U.S. markets close in 6 hours 23 minutes
  • S&P 500

    3,306.93
    +36.97 (+1.13%)
     
  • Dow 30

    26,809.93
    +308.33 (+1.16%)
     
  • Nasdaq

    11,018.01
    +106.42 (+0.98%)
     
  • Russell 2000

    1,538.48
    -23.10 (-1.48%)
     
  • Crude Oil

    35.47
    -0.32 (-0.89%)
     
  • Gold

    1,890.80
    +10.90 (+0.58%)
     
  • Silver

    24.00
    +0.35 (+1.48%)
     
  • EUR/USD

    1.1639
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    0.8350
    -0.0250 (-2.91%)
     
  • GBP/USD

    1.2910
    -0.0044 (-0.34%)
     
  • USD/JPY

    104.7330
    +0.0980 (+0.09%)
     
  • BTC-USD

    13,414.26
    -293.45 (-2.14%)
     
  • CMC Crypto 200

    262.14
    -5.95 (-2.22%)
     
  • FTSE 100

    5,646.94
    +69.67 (+1.25%)
     
  • Nikkei 225

    23,295.48
    +318.35 (+1.39%)
     

It Might Not Be A Great Idea To Buy Pfizer Inc. (NYSE:PFE) For Its Next Dividend

Simply Wall St
·4 mins read

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Pfizer Inc. (NYSE:PFE) is about to go ex-dividend in just two days. Ex-dividend means that investors that purchase the stock on or after the 5th of November will not receive this dividend, which will be paid on the 1st of December.

Pfizer's next dividend payment will be US$0.38 per share. Last year, in total, the company distributed US$1.52 to shareholders. Last year's total dividend payments show that Pfizer has a trailing yield of 4.3% on the current share price of $35.48. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.

See our latest analysis for Pfizer

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Pfizer paid out 96% of its earnings, which is more than we're comfortable with, unless there are mitigating circumstances. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. It paid out more than half (64%) of its free cash flow in the past year, which is within an average range for most companies.

It's good to see that while Pfizer's dividends were not well covered by profits, at least they are affordable from a cash perspective. Still, if this were to happen repeatedly, we'd be concerned about whether the dividend is sustainable in a downturn.

Click here to see the company's payout ratio, plus analyst estimates of its future dividends.

historic-dividend
historic-dividend

Have Earnings And Dividends Been Growing?

Companies that aren't growing their earnings can still be valuable, but it is even more important to assess the sustainability of the dividend if it looks like the company will struggle to grow. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. With that in mind, we're not enthused to see that Pfizer's earnings per share have remained effectively flat over the past five years. We'd take that over an earnings decline any day, but in the long run, the best dividend stocks all grow their earnings per share.

The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Since the start of our data, 10 years ago, Pfizer has lifted its dividend by approximately 7.8% a year on average.

To Sum It Up

Is Pfizer worth buying for its dividend? Earnings per share have barely moved in recent times, and the company is paying out an uncomfortably high percentage of its income. Fortunately its cash generation was somewhat stronger. Bottom line: Pfizer has some unfortunate characteristics that we think could lead to sub-optimal outcomes for dividend investors.

So if you're still interested in Pfizer despite it's poor dividend qualities, you should be well informed on some of the risks facing this stock. For example, we've found 4 warning signs for Pfizer that we recommend you consider before investing in the business.

If you're in the market for dividend stocks, we recommend checking our list of top dividend stocks with a greater than 2% yield and an upcoming dividend.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.